Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAM | P19021 | 1/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | PLIN1 | O60240 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 2/20 | 0.47 |
| ▸ | PLIN5 | Q00G26 | 2/20 | 0.47 |
| ▸ | ABHD5 | Q8WTS1 | 2/20 | 0.47 |
| ▸ | TNKS | O95271 | 1/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL597265 | 0.81 | PAM (0.63) | PAMGLATDP1ALOX15MAOB | |
| SCHEMBL9427036 | 0.79 | GLA (0.57) | GLATDP1ALOX15MAOBALDH1A1 | |
| SCHEMBL9427039 | 0.79 | GLA (0.57) | GLATDP1ALOX15MAOBALDH1A1 | |
| SCHEMBL827256 | 0.78 | PAM (0.70) | PAMGLATDP1MAOBALDH1A1 | |
| SCHEMBL1230617 | 0.78 | PAM (0.59) | PAMGLATDP1ALOX15MAOB | |
| SCHEMBL827257 | 0.78 | PAM (0.70) | PAMGLATDP1MAOBALDH1A1 | |
| SCHEMBL8089036 | 0.78 | PAM (0.59) | PAMGLATDP1ALOX15MAOB | |
| SCHEMBL9427283 | 0.76 | GLA (0.53) | GLATDP1ALOX15MAOBALDH1A1 | |
| SCHEMBL9427285 | 0.76 | GLA (0.53) | GLATDP1ALOX15MAOBALDH1A1 | |
| Water SCHEMBL7165212 | 0.76 | PAM (0.57) | PAMGLATDP1ALOX15MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1334111-A4 | PHOSPHINOAMIDITE CARBOXYLATES AND ANALOGS THEREOF IN THE SYNTHESIS OF OLIGONUCLEOTIDES HAVING REDUCED INTERNUCLEOTIDE CHARGE | DELLINGER DOUGLAS J (US) | 2007-01-24 | — | — | EP | claimed |
| US-7067641-B2 | Phosphinoamidite carboxylates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge | LIEVRE CORNU LLC (US) | 2006-06-27 | — | — | US | claimed |
| US-20040116687-A1 | oligonucleotides having reduced internucleotide charge and enhanced nuclease resistance | AGILENT TECHNOLOGIES, INC. | 2004-06-17 | — | — | US | claimed |
| EP-1334111-A2 | PHOSPHINOAMIDITE CARBOXYLATES AND ANALOGS THEREOF IN THE SYNTHESIS OF OLIGONUCLEOTIDES HAVING REDUCED INTERNUCLEOTIDE CHARGE | Dellinger, Douglas J. (US) | 2003-08-13 | — | — | EP | claimed |
| WO-2002032912-A2 | PHOSPHINOAMIDITE CARBOXYLATES AND ANALOGS THEREOF IN THE SYNTHESIS OF OLIGONUCLEOTIDES HAVING REDUCED INTERNUCLEOTIDE CHARGE | DELLINGER DOUGLAS J (US) | 2002-04-25 | — | — | WO | claimed |
| US-8846898-B2 | Phosphinoamidite carboxylates and analogs thereof in the synthesis of oligonucleotide having reduced internucleotide charge | Lieure Cornu LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-20100311960-A1 | Phosphinoamidite Carboxylates and Analogs Thereof in the Synthesis of Oligonucleotide Having Reduced Internucleotide Charge | LIEVRE CORNU LLC (US) | 2010-12-09 | — | — | US | disclosed |
| US-7745591-B2 | phosphinocarboxylate and phosphonocarboxylate oligonucleotides having enhanced nuclease resistance | Lievre Cornu, LLC (US) | 2010-06-29 | — | — | US | disclosed |
| EP-1334111-A4 | PHOSPHINOAMIDITE CARBOXYLATES AND ANALOGS THEREOF IN THE SYNTHESIS OF OLIGONUCLEOTIDES HAVING REDUCED INTERNUCLEOTIDE CHARGE | DELLINGER DOUGLAS J (US) | 2007-01-24 | — | — | EP | disclosed |
| US-20060293511-A1 | phosphinocarboxylate and phosphonocarboxylate oligonucleotides having enhanced nuclease resistance | LIEVRE CORNU LLC (US) | 2006-12-28 | — | — | US | disclosed |
| US-7067641-B2 | Phosphinoamidite carboxylates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge | LIEVRE CORNU LLC (US) | 2006-06-27 | — | — | US | disclosed |
| US-20040116687-A1 | oligonucleotides having reduced internucleotide charge and enhanced nuclease resistance | AGILENT TECHNOLOGIES, INC. | 2004-06-17 | — | — | US | disclosed |
| EP-1334111-A2 | PHOSPHINOAMIDITE CARBOXYLATES AND ANALOGS THEREOF IN THE SYNTHESIS OF OLIGONUCLEOTIDES HAVING REDUCED INTERNUCLEOTIDE CHARGE | Dellinger, Douglas J. (US) | 2003-08-13 | — | — | EP | disclosed |
| WO-2002032912-A2 | PHOSPHINOAMIDITE CARBOXYLATES AND ANALOGS THEREOF IN THE SYNTHESIS OF OLIGONUCLEOTIDES HAVING REDUCED INTERNUCLEOTIDE CHARGE | DELLINGER DOUGLAS J (US) | 2002-04-25 | — | — | WO | disclosed |
| EP-1144371-A1 | BENZENESULPHONAMIDE DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-10-17 | — | — | EP | disclosed |
| EP-1144372-A1 | SULPHOHYDROXAMIC ACIDS AND SULPHOHYDROXAMATES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000042003-A1 | BENZENESULFONAMIDE DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | disclosed |
| WO-2000042002-A1 | SULPHOHYDROXAMIC ACIDS AND SULPHOHYDROXAMATES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311960-A1 | Phosphinoamidite Carboxylates and Analogs Thereof in the Synthesis of Oligonucleotide Having Reduced Internucleotide Charge | NSUN2, POLL, DUT | PAM 481/4885GLA 2798/4885TDP1 485/4885 |
| US-20060293511-A1 | phosphinocarboxylate and phosphonocarboxylate oligonucleotides having enhanced nuclease resistance | NSUN2, ADAR, POLL | PAM 1405/4885GLA 2377/4885TDP1 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.